Clinical lymphoma, myeloma & leukemia · 2026
Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jinguji Atsushi, Kurosawa Shuhei, Toya Takashi, Kato Kana, Sadaga Yasutaka, Kondo Kaori, Ouchi Fumihiko, Shimabukuro Masashi, Shingai Naoki, Shimizu Hiroaki, Najima Yuho, Haraguchi Kyoko, Doki Noriko
Аннотация
BACKGROUND: FLT3 mutations in acute myeloid leukemia (AML) are associated with high relapse rates even after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
OBJECTIVES: We evaluated changes in transplant outcomes in patients with FLT3-ITD-mutated AML and detailed real-world experiences with post-transplant gilteritinib maintenance.
STUDY DESIGN: This study included adult patients (≥16 years) with FLT3-ITD-mutated AML who were eligible for allo-HSCT. The patients were stratified into the FLT3i era (2019-2024) and the pre-FLT3i era (2012-2018). The primary endpoint was the 3-year overall survival (OS).
RESULTS: Ninety-three patients were included, 43 in the pre-FLT3i era and 50 in the FLT3i era. The FLT3i era was associated with a significantly higher 3-year OS from diagnosis (65.7% vs. 44.3%; 95% CI, 48.0-78.6 vs. 28.9-58.6). Thirty-eight patients and 48 patients, respectively, underwent allo-HSCT. The 3-year OS from allo-HSCT was 47.4% (95% CI, 31.0-62.1) and 60.6% (95% CI, 41.8-75.0), respectively (P = .11). Multivariate analysis revealed that myelodysplastic change, non-CR disease status at allo-HSCT, and a higher HCT-CI (≥2) were adverse prognostic factors. In the FLT3i era, 6 patients received maintenance therapy with gilteritinib. The median interval from HSCT to the initiation of gilteritinib was 30 days (range, 18-69). Five patients remained relapse-free, with a median treatment duration of 583 days. The 2-year OS rate was 83.3% (95% CI, 27.3-97.5).
CONCLUSIONS: Although the OS from diagnosis improved significantly in the FLT3i era, relapse after allo-HSCT remained a substantial challenge. Further studies are needed to optimize FLT3i maintenance therapy strategies.
OBJECTIVES: We evaluated changes in transplant outcomes in patients with FLT3-ITD-mutated AML and detailed real-world experiences with post-transplant gilteritinib maintenance.
STUDY DESIGN: This study included adult patients (≥16 years) with FLT3-ITD-mutated AML who were eligible for allo-HSCT. The patients were stratified into the FLT3i era (2019-2024) and the pre-FLT3i era (2012-2018). The primary endpoint was the 3-year overall survival (OS).
RESULTS: Ninety-three patients were included, 43 in the pre-FLT3i era and 50 in the FLT3i era. The FLT3i era was associated with a significantly higher 3-year OS from diagnosis (65.7% vs. 44.3%; 95% CI, 48.0-78.6 vs. 28.9-58.6). Thirty-eight patients and 48 patients, respectively, underwent allo-HSCT. The 3-year OS from allo-HSCT was 47.4% (95% CI, 31.0-62.1) and 60.6% (95% CI, 41.8-75.0), respectively (P = .11). Multivariate analysis revealed that myelodysplastic change, non-CR disease status at allo-HSCT, and a higher HCT-CI (≥2) were adverse prognostic factors. In the FLT3i era, 6 patients received maintenance therapy with gilteritinib. The median interval from HSCT to the initiation of gilteritinib was 30 days (range, 18-69). Five patients remained relapse-free, with a median treatment duration of 583 days. The 2-year OS rate was 83.3% (95% CI, 27.3-97.5).
CONCLUSIONS: Although the OS from diagnosis improved significantly in the FLT3i era, relapse after allo-HSCT remained a substantial challenge. Further studies are needed to optimize FLT3i maintenance therapy strategies.